Tipranks Press Release.
PROCEPT BioRobotics (PRCT) is back in focus after reporting third quarter 2026 results that paired 18% year-over-year revenue growth with a wider net loss, while management held firm on full year guidance. Investors have reacted cautiously to the latest update, with the 1-day share price return declining 6.4% to leave PROCEPT BioRobotics at US$20.27. That move sits against a 30-day share price gain of 15.8%, a year-to-date share price decline of 34.1%, and a 1-year total shareholder return...
PROCEPT BIOROBO (PRCT) delivered earnings and revenue surprises of -17.95% and -1.78%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
PROCEPT BIOROBO (PRCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PROCEPT BioRobotics’ Aquablation may ease BPH symptoms while preserving function. Read here for a detailed investment analysis of PRCT stock.
SAN JOSE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2026 after market close on Wednesday, November 4, 2026. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to
Why this governance shift at PROCEPT BioRobotics matters for investors A fresh investor lawsuit and the appointment of cardiac surgeon Dr. Michael Mack to the board put PROCEPT BioRobotics (PRCT) under a governance spotlight that stockholders will want to understand closely. Recent trading tells a story of pressure rather than momentum for PROCEPT BioRobotics, with the share price delivering a 30 day return of down 21.31% and a year to date share price return of down 41.77%. The 1 year total...
In early October 2026, PROCEPT BioRobotics added veteran cardiac surgeon Dr. Michael Mack to its board as an independent Class II director, while also facing a newly filed securities lawsuit alleging undisclosed discounting practices that inflated reported U.S. handpiece demand and related operational risks. The combination of a medically seasoned, research-focused director and allegations about bulk-order discounting practices raises important questions about PROCEPT’s governance,...
Detailed price information for Procept Biorobotics Corp (PRCT-Q) from The Globe and Mail including charting and trades.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Detailed price information for Procept Biorobotics Corp (PRCT-Q) from The Globe and Mail including charting and trades.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Detailed price information for Procept Biorobotics Corp (PRCT-Q) from The Globe and Mail including charting and trades.
Detailed price information for Procept Biorobotics Corp (PRCT-Q) from The Globe and Mail including charting and trades.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Detailed price information for Procept Biorobotics Corp (PRCT-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.